Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (495)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06441045 | Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI | not yet recruiting | Phase 2 | 112 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06218524 | The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM | not yet recruiting | Phase 2 | 200 | Southern Medical University, ChinaOTHER | 0 | Jan 23, 2024 |
| clinicaltrials |
| NCT05540275 | Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma | not yet recruiting | Phase 2 | 30 | Henan Provincial People's HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05842746 | Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma | not yet recruiting | Phase 2 | 74 | Peking Union Medical College HospitalOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05502991 | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma | not yet recruiting | Phase 2 | 60 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05303727 | Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma | not yet recruiting | Phase 2 | 64 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05347641 | Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma | not yet recruiting | Phase 2 | 23 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Apr 26, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jun 4, 2024source: clinicaltrials